Press Release
BIOGEN AND INNOCARE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ORELABRUTINIB, AN INNOVATIVE CNS PENETRANT BTK INHIBITOR FOR THE POTENTIAL TREATMENT OF MULTIPLE SCLEROSIS
13 Jul, 2021
212
3482
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China
25 Jun, 2021
87
3471
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL
28 Jun, 2021
173
3475
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
18 Jun, 2021
139
3467
InnoCare Wins Three Awards
11 Jun, 2021
134
3464
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
09 Jun, 2021
141
3456
InnoCare Inaugurates Its Shanghai Branch
08 Jun, 2021
122
3452
InnoCare Presents Latest Clinical Data of pan-FGFR Inhibitor Gunagratinib at the 2021 ASCO Annual Meeting
04 Jun, 2021
148
3448